Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • USFDA inspection at...

    USFDA inspection at Cipla manufacturing facility in Goa, warning letter issued

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-27T13:56:25+05:30  |  Updated On 27 Feb 2020 1:56 PM IST
    USFDA inspection at Cipla manufacturing facility in Goa, warning letter issued

    New Delhi: Drug firm Cipla recently announced that it has received a warning letter from USFDA for its goa Manufacturing Facility.

    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, further to the earlier communication on the Goa manufacturing facility inspection conducted from 16-27 September 2019 by the United States Food and Drug Administration (USFDA), the Company has received a Warning Letter from USFDA. The Company remains committed to maintaining the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

    The copy of this is also submitted to BSE Ltd, National Stock Exchange of India Ltd and SOCIETE DE LA BOURSE DE LUXEMBOURG.This information is provided by the Rajendra Chopra, Company Secretary & Compliance Officer, Cipla Limited

    Medical Dialogues had earlier reported that in January 2020, Cipla had received observations from the USFDA for its Goa manufacturing facility. It had then said that the developments will not have any material impact on the company's US business at this stage.

    "The United States Food and Drug Administration (USFDA) has classified the inspection conducted at its Goa manufacturing facility from 16-27 September 2019 as Official Action Indicated (OAI). The company does not believe that this will have any material impact on the US business at this stage," the drug major said in an exchange filing.

    Read also: Cipla gets USFDA observations for its Goa facility

    Read also: Cipla arm inks pact for anti-psychotic drug Quetiapine

    Founded in 1935, Cipla an Indian multinational Pharmaceutical company. Driven by the same purpose, Cipla has extended its presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, the company has deep presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.

    ciplausfdacipla goa

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok